Because of the regulatory effects on both p-JAK and p-STAT3 expressions, our present study indicated that AETW might be a promising drug as a JAK activation inhibitor used in the targeted treatment of LC. This evidence concerns the gene STAT3 and laryngotracheoesophageal cleft.